ARWR: License and Collaboration Deal with Sarepta Includes 825 Million Upon Closing

203 Views04 Dec 2024 01:00
Issuer-paid
On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global licensing and collaboration agreement with Sarepta Therapeutics...
What is covered in the Full Insight:
  • Introduction to ARWR-Sarepta Deal
  • Financial Details of the Agreement
  • Covered Clinical and Preclinical Programs
  • Strategic Implications for Arrowhead
  • Risks and Considerations
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Zacks Small Cap Research
Research Coverage on Small and Micro-Cap Companies
Zacks Small Cap Research
Equity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x